drugset / Trial / NCT07250386
A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
Phase 1
Recruiting
48 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Chongqing Precision Biotech Co., Ltd · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Timeline
- Start
- 2025-10-13
- Primary completion
- 2028-06-30
- Completion
- 2028-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEA-targeted CAR-T | Cell therapy | — | Intravenous |